The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Phase III CARES: anselamimab mechanism of action in AL amyloidosis
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, discuses the randomized Phase III CARES study (NCT04512235, NCT04504825) evaluating anselamimab in patients with light-chain (AL) amyloidosis. Dr Wechalekar explains that anselamimab is an anti-fibril antibody that binds amyloid fibrils, activates macrophages, and promotes the clearance of amyloid from affected tissues, with promising results demonstrated in animal models. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the CARES trial is a randomized controlled Phase III clinical trial of a drug called anselamimab. Anselamimab is an antibody targeted towards amyloid fibrils. It has been developed originally in Tennessee as 11-1F4, then further developed as anselamimab, which targets both kappa and lambda light chain fibrils. It binds the fibrils. Once it binds the fibrils, it leads to activation of macrophages, which will then lead to engulfing of the amyloid deposits with progressive clearance of the amyloid deposits...
So the CARES trial is a randomized controlled Phase III clinical trial of a drug called anselamimab. Anselamimab is an antibody targeted towards amyloid fibrils. It has been developed originally in Tennessee as 11-1F4, then further developed as anselamimab, which targets both kappa and lambda light chain fibrils. It binds the fibrils. Once it binds the fibrils, it leads to activation of macrophages, which will then lead to engulfing of the amyloid deposits with progressive clearance of the amyloid deposits. In animal models where amyloidomas were induced by externally injecting light chains, the anselamimab antibody was able to cause amyloid clearance in both kappa as well as lambda amyloidomas. It seems to be more effective in binding to kappa light chains and clearing kappa amyloidomas than lambda amyloidosis. So it’s an antifibril antibody designed to target the amyloid protein deposits and tissues to accelerate the clearance and lead to improvement in organ function.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
